Literature DB >> 15618181

Invasiveness of serotypes and clones of Streptococcus pneumoniae among children in Finland.

William P Hanage1, Tarja H Kaijalainen, Ritva K Syrjänen, Kari Auranen, Maija Leinonen, P Helena Mäkelä, Brian G Spratt.   

Abstract

Streptococcus pneumoniae (the pneumococcus) causes diseases from otitis media to life-threatening invasive infection. The species is extremely antigenically and clonally diverse. We wished to determine odds ratios (ORs) for serotypes and clones of S. pneumoniae that cause invasive disease in Finland. A total of 224 isolates of S. pneumoniae from cases of invasive disease in children <2 years of age in Finland between 1995 and 1999 were serotyped, and sequence types (STs) were determined by multilocus sequence typing. These STs were compared with a previously published carriage data set. STs from invasive disease were significantly less diverse than those from carriage (invasive disease, 0.038 +/- 0.01; carriage, 0.019 +/- 0.005). The ORs of serotypes 14, 18C, 19A, and 6B were significantly greater than 1, indicating association with invasive disease. The ORs of 6A and 11A were significantly less than 1. The difference between 6A and 6B is significant, which suggests that relatively subtle changes in the capsule may have a dramatic effect upon disease potential. We found that ST 156, the Spain(9V)-3 clone which mainly expressed serotype 14 in Finland, is strongly associated with invasive disease (OR, 10.1; 95% confidence interval, 1.3 to 79.5). Significant associations with invasive disease were also detected for STs 482, 191, 124, and 138, and associations with carriage were detected for STs 485 and 62. These results demonstrate the invasive phenotype of the serotype 14 variant of the Spain(9V)-3 clone and differences between members of the same serogroup in invasive disease potential.

Entities:  

Mesh:

Year:  2005        PMID: 15618181      PMCID: PMC538975          DOI: 10.1128/IAI.73.1.431-435.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  13 in total

1.  Prevention of pneumococcal disease by vaccination: does serotype replacement matter?

Authors:  B G Spratt; B M Greenwood
Journal:  Lancet       Date:  2000-10-07       Impact factor: 79.321

2.  Determining confidence intervals when measuring genetic diversity and the discriminatory abilities of typing methods for microorganisms.

Authors:  H Grundmann; S Hori; G Tanner
Journal:  J Clin Microbiol       Date:  2001-11       Impact factor: 5.948

3.  Clonal relationships between invasive and carriage Streptococcus pneumoniae and serotype- and clone-specific differences in invasive disease potential.

Authors:  Angela B Brueggemann; David T Griffiths; Emma Meats; Timothy Peto; Derrick W Crook; Brian G Spratt
Journal:  J Infect Dis       Date:  2003-04-04       Impact factor: 5.226

4.  Temporal and geographic stability of the serogroup-specific invasive disease potential of Streptococcus pneumoniae in children.

Authors:  Angela B Brueggemann; Timothy E A Peto; Derrick W Crook; Jay C Butler; Karl G Kristinsson; Brian G Spratt
Journal:  J Infect Dis       Date:  2004-08-25       Impact factor: 5.226

5.  Effect of clonal and serotype-specific properties on the invasive capacity of Streptococcus pneumoniae.

Authors:  A Sandgren; K Sjostrom; B Olsson-Liljequist; B Christensson; A Samuelsson; G Kronvall; B Henriques Normark
Journal:  J Infect Dis       Date:  2004-02-16       Impact factor: 5.226

6.  Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group.

Authors:  S Black; H Shinefield; B Fireman; E Lewis; P Ray; J R Hansen; L Elvin; K M Ensor; J Hackell; G Siber; F Malinoski; D Madore; I Chang; R Kohberger; W Watson; R Austrian; K Edwards
Journal:  Pediatr Infect Dis J       Date:  2000-03       Impact factor: 2.129

7.  Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I.

Authors:  W P Hausdorff; J Bryant; P R Paradiso; G R Siber
Journal:  Clin Infect Dis       Date:  2000-01       Impact factor: 9.079

8.  Efficacy of a pneumococcal conjugate vaccine against acute otitis media.

Authors:  J Eskola; T Kilpi; A Palmu; J Jokinen; J Haapakoski; E Herva; A Takala; H Käyhty; P Karma; R Kohberger; G Siber; P H Mäkelä
Journal:  N Engl J Med       Date:  2001-02-08       Impact factor: 91.245

9.  Ability of pneumococcal serotypes and clones to cause acute otitis media: implications for the prevention of otitis media by conjugate vaccines.

Authors:  William P Hanage; Kari Auranen; Ritva Syrjänen; Elja Herva; P Helena Mäkelä; Terhi Kilpi; Brian G Spratt
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

10.  A multilocus sequence typing scheme for Streptococcus pneumoniae: identification of clones associated with serious invasive disease.

Authors:  Mark C Enright; Brian G Spratt
Journal:  Microbiology (Reading)       Date:  1998-11       Impact factor: 2.777

View more
  68 in total

1.  Contribution of serotype and genetic background to virulence of serotype 3 and serogroup 11 pneumococcal isolates.

Authors:  Lauren J McAllister; Abiodun D Ogunniyi; Uwe H Stroeher; Amanda J Leach; James C Paton
Journal:  Infect Immun       Date:  2011-09-19       Impact factor: 3.441

2.  Analysis of invasiveness of pneumococcal serotypes and clones circulating in Portugal before widespread use of conjugate vaccines reveals heterogeneous behavior of clones expressing the same serotype.

Authors:  Raquel Sá-Leão; Francisco Pinto; Sandra Aguiar; Sónia Nunes; João A Carriço; Nelson Frazão; Natacha Gonçalves-Sousa; José Melo-Cristino; Hermínia de Lencastre; Mário Ramirez
Journal:  J Clin Microbiol       Date:  2011-01-26       Impact factor: 5.948

3.  Low invasiveness of pneumococcal serotype 11A is linked to ficolin-2 recognition of O-acetylated capsule epitopes and lectin complement pathway activation.

Authors:  Allison M Brady; Juan J Calix; Jigui Yu; Kimball Aaron Geno; Gary R Cutter; Moon H Nahm
Journal:  J Infect Dis       Date:  2014-03-27       Impact factor: 5.226

4.  Distribution and invasiveness of Streptococcus pneumoniae serotypes in Switzerland, a country with low antibiotic selection pressure, from 2001 to 2004.

Authors:  Andreas Kronenberg; Phillip Zucs; Sara Droz; Kathrin Mühlemann
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

5.  Genomic diversity between strains of the same serotype and multilocus sequence type among pneumococcal clinical isolates.

Authors:  Nuno A Silva; Jackie McCluskey; Johanna M C Jefferies; Jason Hinds; Andrew Smith; Stuart C Clarke; Tim J Mitchell; Gavin K Paterson
Journal:  Infect Immun       Date:  2006-06       Impact factor: 3.441

Review 6.  Serotype replacement in disease after pneumococcal vaccination.

Authors:  Daniel M Weinberger; Richard Malley; Marc Lipsitch
Journal:  Lancet       Date:  2011-04-12       Impact factor: 79.321

Review 7.  Patterns of antigenic diversity and the mechanisms that maintain them.

Authors:  Marc Lipsitch; Justin J O'Hagan
Journal:  J R Soc Interface       Date:  2007-10-22       Impact factor: 4.118

8.  Clinical features and outcomes of serotype 19A invasive pneumococcal disease in Calgary, Alberta.

Authors:  Leah J Ricketson; Otto G Vanderkooi; Melissa L Wood; Jenine Leal; James D Kellner
Journal:  Can J Infect Dis Med Microbiol       Date:  2014-03       Impact factor: 2.471

9.  Rapid and easy identification of capsular serotypes of Streptococcus pneumoniae by use of fragment analysis by automated fluorescence-based capillary electrophoresis.

Authors:  Laura Selva; Eva del Amo; Pedro Brotons; Carmen Muñoz-Almagro
Journal:  J Clin Microbiol       Date:  2012-08-08       Impact factor: 5.948

10.  Host-pathogen interactions and prognosis of critically ill immunocompetent patients with pneumococcal pneumonia: the nationwide prospective observational STREPTOGENE study.

Authors:  Jean-Pierre Bedos; Emmanuelle Varon; Raphael Porcher; Pierre Asfar; Yves Le Tulzo; Bruno Megarbane; Armelle Mathonnet; Anthony Dugard; Anne Veinstein; Kader Ouchenir; Shidasp Siami; Jean Reignier; Arnaud Galbois; Joël Cousson; Sébastien Preau; Olivier Baldesi; Jean-Philippe Rigaud; Bertrand Souweine; Benoit Misset; Frederic Jacobs; Florent Dewavrin; Jean-Paul Mira
Journal:  Intensive Care Med       Date:  2018-11-19       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.